Citius Oncology Files 8-K Report

Ticker: CTOR · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1851484

Citius Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyCitius Oncology, INC. (CTOR)
Form Type8-K
Filed DateJan 6, 2025
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: CTZX

TL;DR

CITIUS filed an 8-K on Jan 6, 2025. Standard update, check for details.

AI Summary

On January 6, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates Citius Oncology is providing updates or required disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events, making the immediate risk level low.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Citius Oncology, Inc. in this 8-K filing?

The provided excerpt does not detail the specific 'Other Events' being reported, only that this item is included in the filing.

What is the significance of the 'Financial Statements and Exhibits' being listed as an item in this 8-K?

This indicates that Citius Oncology is providing financial statements or exhibits as part of this filing, which could include important financial data or supporting documents.

When was Citius Oncology, Inc. incorporated, and in which jurisdiction?

Citius Oncology, Inc. was incorporated in Delaware, as stated in the filing.

What is the principal executive office address for Citius Oncology, Inc.?

The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.

What is the SEC file number for Citius Oncology, Inc.?

The SEC file number for Citius Oncology, Inc. is 001-41534.

Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-01-06 08:30:10

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 6, 2025, Citius Oncology, Inc. announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated January 6, 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: January 6, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing